The Technical Analyst
Therapeutics Acquisition [RACA]
Exchange: NASDAQ Sector: Financial Services Industry: Shell Companies
Therapeutics Acquisition Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.44% $10.27
America/New_York / 1 jul 2021 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 085.43 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 105.65 mill |
| Avg Daily Volume: | 0.138 mill |
| RATING 2021-06-30 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||
|---|---|---|---|---|
| 2/20 | 2/20 | 1/21 | 2/21 | |
| Revenue | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | |
| Asset | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -18.15 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE -25.74 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 10.04 - 10.50 ( +/- 2.24%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-06-29 | Kolchinsky Peter | Buy | 209 100 | Common Stock |
| 2021-06-29 | Ra Capital Management, L.p. | Buy | 209 100 | Common Stock |
| 2021-06-24 | Kolchinsky Peter | Buy | 889 218 | Common Stock |
| 2021-06-23 | Ra Capital Management, L.p. | Buy | 0 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 3 transactions |
| Buy: 1 307 418 | Sell: 0 |
Forecast:
01:40 - $8.75
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.27 (2.44% ) |
| Volume | 0.0313 mill |
| Avg. Vol. | 0.138 mill |
| % of Avg. Vol | 22.77 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RACA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RACA
Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was founded in 2020 and is based in Boston, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2021-06-30 16:05:00 - Press Release
Point Biopharma Debuts As Publicly Traded Next-generation Radiotherapeutics Company
Common stock to commence trading on the nasdaq capital market on july 1, 2021 under the ticker symbol “pnt”
2021-06-09 16:30:00 - Press Release
Research Alliance Corp. I Announces Effectiveness Of Registration Statement For Proposed Business Combination With Point
Boston--(business wire)--therapeutics acquisition corp, d/b/a research alliance corp. i, a delaware corporation (“the company”) (nasdaq: raca) announced today that its registration statement on form s-4 (file number 333-254600) (as amended, the “registration statement”), relating to the previously announced business combination (the “business combination”) with point biopharma inc. (“point”), has been declared effective by the u.s. securities and exchange commission (“sec”) and that it will com
2021-06-04 08:30:00 - Press Release
Point Biopharma Announces First Patients Dosed In Phase 3 Study Of Pnt2002 For Mcrpc
Indianapolis--(business wire)--point biopharma inc. (point), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its phase 3 splash study evaluating the efficacy of pnt2002, the company's investigational 177lu-psma targeted radioligand therapy for patients with psma expressing metastatic castration resistant prostate cancer (mcrpc) who are not eligible for
2021-06-04 06:30:00 - Press Release
Point Biopharma Announces First Patients Dosed In Phase 3 Study Of Pnt2002 For Mcrpc
Indianapolis, june 04, 2021 (globe newswire) -- point biopharma inc. (point), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its phase 3 splash study evaluating the efficacy of pnt2002, the company's investigational 177lu-psma targeted radioligand therapy for patients with psma expressing metastatic castration resistant prostate cancer (mcrpc) who are not eligible for chemotherapy.
Latest News
2021-06-30 16:05:00 - GlobeNewsWire
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”
2021-06-09 16:30:00 - Business Wire
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its registration statement on Form S-4 (File Number 333-254600) (as amended, the “Registration Statement”), relating to the previously announced business combination (the “Business Combination”) with POINT Biopharma Inc. (“POINT”), has been declared effective by the U.S. Securities and Exchange Commission (“SEC”) and that it will com
2021-06-04 08:30:00 - Business Wire
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
INDIANAPOLIS--(BUSINESS WIRE)--POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company's investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for
2021-06-04 06:30:00 - GlobeNewsWire
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company's investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer (mCRPC) who are not eligible for chemotherapy.